Proguanil

The dosage of Proguanil depends heavily on whether it is being used for prevention or as part of a combination treatment for active infection. For the prophylaxis (prevention) of malaria, the standard adult dose is typically 200 mg once daily.

• Timing: Prophylaxis should begin 1 to 2 days before entering a malaria-endemic area.
• Duration: The medication must be taken daily throughout the stay and continued for 4 weeks (28 days) after leaving the endemic area. This extended period is crucial because the drug targets the parasite as it emerges from the liver, and stopping too early could allow a latent infection to develop into clinical malaria.
• Combination Treatment: When used with atovaquone for treatment, the adult dose is typically 4 'adult strength' tablets (totaling 400 mg Proguanil) taken as a single dose daily for 3 consecutive days.

Proguanil is approved for use in children, but the dosage is strictly determined by the child's body weight. Pediatric dosing for prophylaxis is generally as follows:

• Under 5 kg: Safety and efficacy have not been firmly established for monotherapy.
• 5–8 kg: 25 mg once daily.
• 9–15 kg: 50 mg once daily.
• 16–25 kg: 75 mg once daily.
• 26–35 kg: 100 mg once daily.
• 36–45 kg: 150 mg once daily.
• Over 45 kg: Standard adult dose of 200 mg once daily.

For combination treatment (with atovaquone), specific pediatric tablets are used, and the number of tablets is calculated based on weight ranges. Always consult a pediatrician for precise dosing, as incorrect dosing in children can lead to treatment failure or toxicity.

Renal Impairment

Because Proguanil is primarily excreted by the kidneys, dosage adjustments are mandatory for patients with decreased kidney function.

• Mild Impairment (CrCl 50-80 mL/min): No adjustment usually required.
• Moderate Impairment (CrCl 30-50 mL/min): The dose may need to be reduced (e.g., 100 mg daily instead of 200 mg).
• Severe Impairment (CrCl < 30 mL/min): Proguanil is generally contraindicated for prophylaxis in patients with severe renal failure due to the high risk of drug accumulation and systemic toxicity.

Hepatic Impairment

No specific dosage adjustment is typically required for mild to moderate hepatic impairment, though the drug should be used with caution as it is metabolized in the liver.

Elderly Patients

No specific age-related dose adjustments are recommended, but healthcare providers should consider the higher likelihood of decreased renal function in the elderly and adjust the dose accordingly.

To ensure the best results and minimize side effects, follow these guidelines:

• Consistency: Take the medication at the same time every day. This maintains a steady level of the drug in your bloodstream.
• With Food: Take Proguanil with a meal or a milky drink. This significantly reduces the risk of stomach upset and nausea.
• Swallow Whole: Tablets should be swallowed whole. If a child cannot swallow tablets, they may be crushed and mixed with a small amount of condensed milk or jam.
• Storage: Store at room temperature (20°C to 25°C), away from moisture, heat, and direct sunlight.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. Missing doses during travel significantly increases your risk of contracting malaria.

Signs of Proguanil overdose may include severe vomiting, abdominal pain, diarrhea, and skin rashes. In severe cases, hematuria (blood in the urine) or reversible hair loss may occur. If an overdose is suspected, seek emergency medical attention or contact a poison control center immediately. Treatment is generally supportive, focusing on gastric lavage and maintaining hydration.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication early without medical guidance, even if you do not feel ill.

Most people tolerate Proguanil well, but like all medications, it can cause side effects. The most frequently reported issues include:

• Gastrointestinal Distress: This is the most common complaint. Patients may experience nausea, mild stomach cramps, and occasional diarrhea. These symptoms are usually transient and can often be mitigated by taking the medication with food.
• Mouth Ulcers (Stomatitis): A unique side effect of Proguanil is the development of small, painful sores inside the mouth or on the tongue. This occurs because the drug's mechanism (folate inhibition) can affect the rapidly dividing cells of the oral mucosa. If these become severe, consult your doctor.
• Loss of Appetite: Some individuals report a temporary decrease in desire to eat, which usually resolves as the body adjusts to the medication.

• Skin Reactions: Mild skin rashes or itching (pruritus) may occur. These are typically not serious but should be monitored.
• Headache and Dizziness: Some patients report mild lightheadedness or headaches shortly after taking their daily dose.
• Vomiting: While nausea is common, actual vomiting is less frequent. If vomiting occurs within one hour of taking the dose, the dose should be repeated once the stomach settles.

• Reversible Hair Loss (Alopecia): In rare instances, prolonged use of Proguanil has been associated with thinning hair. This effect is usually reversible once the medication is discontinued.
• Blood Disorders: Rare cases of thrombocytopenia (low platelet count) or anemia have been reported, particularly in patients with pre-existing renal issues.
• Fever: Unexplained fever may occur as a hypersensitivity reaction.

While rare, some side effects require urgent medical intervention.

> Warning: Stop taking Proguanil and call your doctor immediately if you experience any of the following:

• Anaphylaxis / Severe Allergic Reaction: Symptoms include swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; and severe hives. This is a medical emergency.
• Severe Skin Reactions: The development of blistering, peeling skin, or sores around the eyes, nose, or mouth (which could indicate Stevens-Johnson Syndrome).
• Hepatotoxicity (Liver Injury): Signs include yellowing of the skin or eyes (jaundice), dark urine, pale stools, and severe upper abdominal pain.
• Severe Hematologic Changes: Unusual bruising, bleeding (e.g., nosebleeds or bleeding gums), or signs of infection like persistent sore throat and high fever, which may indicate a drop in white blood cell counts (leukopenia).
• Kidney Dysfunction: A significant change in the amount of urine produced or the presence of blood in the urine.

Proguanil is generally intended for short-term use (the duration of a trip plus 4 weeks). Long-term use (months to years) is sometimes necessary for expatriates or long-term travelers. In these cases, the risk of cumulative side effects like hair thinning or mild suppression of bone marrow function increases slightly. Regular blood counts and renal function monitoring are recommended for individuals taking Proguanil for longer than six months.

No FDA black box warnings currently exist for Proguanil hydrochloride. However, it is vital to adhere to the warnings regarding renal impairment and the risk of malaria breakthrough if doses are missed.

Report any unusual symptoms to your healthcare provider. Even mild side effects should be discussed if they interfere with your ability to complete the full course of prophylaxis.

Proguanil is a highly effective tool for malaria prevention, but it must be used with caution. The most critical safety point is the necessity of compliance. Malaria is a life-threatening disease; taking Proguanil does not guarantee 100% protection. It must be used in conjunction with 'mosquito bite avoidance' measures, such as using insect repellent (DEET), wearing long-sleeved clothing, and sleeping under insecticide-treated bed nets.

There are currently no FDA black box warnings for Proguanil. It is considered to have a favorable safety profile when used as directed in appropriate populations.

• Allergic Reactions: Patients with a known hypersensitivity to Proguanil hydrochloride or any components of the formulation should not take this drug. Anaphylaxis, though rare, has been documented.
• Renal Insufficiency: This is the most significant clinical precaution. Because the kidneys are responsible for clearing Proguanil, patients with impaired renal function are at a high risk for toxic accumulation. In patients with a Creatinine Clearance (CrCl) of less than 30 mL/min, Proguanil is generally avoided for malaria prophylaxis.
• Resistance Patterns: Proguanil resistance is widespread in certain parts of the world (e.g., parts of Southeast Asia and South America). Using Proguanil in an area where the parasites are resistant will not provide protection. Always check current CDC travel notices.
• Folate Deficiency: Since Proguanil inhibits dihydrofolate reductase, it can theoretically exacerbate pre-existing folate deficiency. This is particularly relevant for pregnant women or patients with certain types of anemia.

For standard short-term travelers, intensive lab monitoring is usually not required. However, for specific groups, the following may be necessary:

• Renal Function Tests: Baseline and periodic serum creatinine/BUN tests for patients with known or suspected kidney disease.
• Complete Blood Count (CBC): Periodic monitoring for patients on long-term therapy to ensure no suppression of white blood cells or platelets is occurring.
• Liver Function Tests (LFTs): If signs of hepatic distress appear.

Proguanil generally does not cause significant sedation or cognitive impairment. However, some individuals may experience dizziness or headaches. You should observe how the medication affects you before driving or operating heavy machinery.

There is no direct, major interaction between Proguanil and alcohol. However, alcohol can cause dehydration and may exacerbate the gastrointestinal side effects (nausea/vomiting) of Proguanil. Furthermore, alcohol can mask the early symptoms of malaria or heatstroke. It is generally advised to limit alcohol consumption while taking antimalarials.

Proguanil does not require a tapering period. However, premature discontinuation is a major risk factor for malaria. If you must stop taking the drug due to side effects, you must contact a healthcare provider immediately to switch to an alternative antimalarial. Do not stop the 4-week post-travel course unless directed by a doctor.

> Important: Discuss all your medical conditions, especially kidney disease or history of drug allergies, with your healthcare provider before starting Proguanil.

While Proguanil has fewer severe interactions than some other antimalarials (like mefloquine), certain combinations are strictly avoided:

• Live Oral Typhoid Vaccine: Proguanil may interfere with the immune response to the live attenuated typhoid vaccine (Ty21a). The vaccine should be completed at least 3 days before starting Proguanil.
• Other DHFR Inhibitors: Using Proguanil with other drugs that inhibit dihydrofolate reductase (such as Pyrimethamine) can lead to additive toxicity and severe folate deficiency.

• Warfarin and Oral Anticoagulants: Proguanil may enhance the anticoagulant effect of warfarin, increasing the risk of bleeding. Patients on blood thinners should have their INR (International Normalized Ratio) monitored closely when starting or stopping Proguanil.
• Antacids: Magnesium trisilicate and other antacids may reduce the absorption of Proguanil. It is recommended to separate the administration of antacids and Proguanil by at least 2 to 3 hours.

• CYP2C19 Inhibitors: Drugs that inhibit the CYP2C19 enzyme (such as Omeprazole or certain antidepressants like Fluoxetine) may prevent the conversion of Proguanil to its active metabolite, cycloguanil. This could theoretically reduce the effectiveness of malaria prevention.
• Metformin: There is a theoretical risk of increased lactic acidosis or altered glucose control, though this is rarely clinically significant. Monitor blood glucose if you have diabetes.

• Dairy and High-Fat Meals: Unlike some other drugs, Proguanil's absorption is generally consistent with food. In fact, taking it with milk or a fatty meal is encouraged to protect the stomach lining and reduce nausea.
• Grapefruit Juice: While not as significant as with other drugs, grapefruit juice can affect various CYP enzymes. It is best to avoid large amounts of grapefruit juice to ensure predictable metabolism.

• Folic Acid Supplements: High doses of folic acid might theoretically interfere with the antimalarial action of Proguanil, as the drug works by blocking folate metabolism in the parasite. However, standard multivitamins are generally considered safe and are often recommended for pregnant women taking the drug (under medical supervision).
• St. John’s Wort: This herbal supplement induces various CYP enzymes and could potentially lead to faster clearance of Proguanil from the body, reducing its protective levels.

Proguanil does not typically interfere with common laboratory tests, but it may occasionally cause a false elevation in serum creatinine if certain assay methods are used. Always inform lab personnel of the medications you are taking.

Mechanism Summary Table:

| Interacting Drug | Mechanism | Clinical Consequence |

|---|---|---|

| Warfarin | Unknown/Metabolic | Increased bleeding risk (Elevated INR) |

| Antacids | Physical Adsorption | Reduced Proguanil efficacy |

| Omeprazole | CYP2C19 Inhibition | Reduced active metabolite (Cycloguanil) |

| Typhoid Vaccine | Antibacterial effect | Reduced vaccine effectiveness |

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and cold medications.

There are specific scenarios where Proguanil must never be used due to the risk of life-threatening complications:

1. 1Known Hypersensitivity: If a patient has previously experienced an allergic reaction (rash, hives, swelling, or anaphylaxis) to Proguanil or any biguanide derivative, the drug is strictly contraindicated.
2. 2Severe Renal Impairment (for Prophylaxis): In patients with a Creatinine Clearance (CrCl) of less than 30 mL/min, Proguanil should not be used for malaria prevention. Because the drug is cleared by the kidneys, severe impairment leads to toxic levels in the blood, which can cause bone marrow suppression and severe gastrointestinal ulceration.
3. 3Resistance Areas: While not a physiological contraindication, using Proguanil as monotherapy in regions with known high-level resistance is clinically contraindicated because it provides a false sense of security while offering no protection against malaria.

Relative contraindications require a careful risk-benefit analysis by a physician:

• Pregnancy: Proguanil should only be used in pregnancy if the risk of malaria (which is devastating to both mother and fetus) outweighs the theoretical risk of folate inhibition. If used, supplemental folic acid (5 mg daily) is usually required.
• History of Hematologic Disorders: Patients with pre-existing anemia or leukopenia should be monitored closely, as Proguanil can rarely affect blood cell counts.
• Epilepsy: While Proguanil is safer than mefloquine for patients with seizures, any antimalarial should be used with caution in patients with poorly controlled epilepsy.

There is a potential for cross-sensitivity between Proguanil and other biguanide compounds. If you have had an allergic reaction to other antiprotozoal biguanides, inform your doctor immediately. There is no known cross-sensitivity between Proguanil and common antibiotics like penicillin or sulfa drugs.

> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and allergy history, before prescribing Proguanil. Never take someone else's antimalarial medication.

Malaria in pregnancy is a significant cause of maternal mortality, miscarriage, and low birth weight. Therefore, prevention is critical.

• FDA/TGA Category: Proguanil is generally considered one of the safer antimalarials during pregnancy when compared to alternatives.
• Risks: The primary concern is that Proguanil is a folate antagonist. To mitigate the risk of neural tube defects or other folate-related issues, the WHO and other bodies recommend that pregnant women taking Proguanil also take a daily supplement of 5 mg of folic acid.
• Clinical Use: It is often used in the second and third trimesters when travel to endemic areas is unavoidable.

Proguanil is excreted into breast milk in very small amounts. The amount ingested by the infant is generally considered too small to be harmful, but it is also not enough to protect the infant from malaria. Infants who are breastfeeding still require their own weight-appropriate malaria prophylaxis if they are in an endemic area. No adverse effects in nursing infants have been documented at standard maternal doses.

Proguanil is approved for use in children and infants weighing more than 5 kg. The primary challenge in pediatric use is ensuring the child receives the full dose, as the tablets can be bitter. Crushing the tablet and mixing it with food is a common strategy. Growth and development do not appear to be affected by short-term prophylactic use of Proguanil.

Elderly patients are at a higher risk for adverse effects primarily due to the natural decline in renal function associated with aging.

• Renal Clearance: Healthcare providers should calculate the estimated GFR (Glomerular Filtration Rate) before prescribing.
• Polypharmacy: The elderly are more likely to be on medications like warfarin or metformin, which interact with Proguanil. Careful medication reconciliation is required.

This is the most critical special population for Proguanil.

• Mild (CrCl 50-80 mL/min): Standard dosing.
• Moderate (CrCl 30-50 mL/min): Dose reduction is necessary (usually half the standard dose).
• Severe (CrCl < 30 mL/min): Contraindicated for prophylaxis. For treatment of active malaria in this population, alternative agents are preferred, or the dose must be extremely carefully titrated in a hospital setting.

Since Proguanil requires hepatic conversion to cycloguanil, patients with severe liver cirrhosis may have reduced levels of the active drug. While no standard dose adjustment exists for mild-to-moderate hepatic impairment, clinical monitoring for efficacy is advised in severe cases.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying kidney issues.

Proguanil is a pro-drug that is metabolized in the liver by the cytochrome P450 enzyme CYP2C19 into its active form, cycloguanil. Cycloguanil is a selective inhibitor of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase (DHFR-TS) in the malaria parasite.

By inhibiting DHFR, the drug prevents the parasite from converting dihydrofolate into tetrahydrofolate. Tetrahydrofolate is a vital precursor for the synthesis of pyrimidines (thymidylate), which are essential building blocks of DNA. Without the ability to synthesize DNA, the parasite cannot replicate. Human DHFR is significantly different in structure from the parasite's version, which allows the drug to target the parasite with high selectivity and relatively low toxicity to the host.

Proguanil exhibits a slow onset of action against the blood stages of the parasite, which is why it is not used alone for acute treatment. However, it is highly effective against the primary tissue stages (liver stages) of P. falciparum. This is known as causal prophylaxis. It prevents the parasites from maturing in the liver and entering the bloodstream. The duration of effect is linked to its daily dosing schedule; because the half-life is relatively short (under 24 hours), daily administration is required to maintain protective plasma concentrations.

| Parameter | Value |

|---|---|

| Bioavailability | >95% (Extensively absorbed) |

| Protein Binding | ~75% (Primarily to albumin) |

| Half-life | 12–21 hours (Proguanil); 12–15 hours (Cycloguanil) |

| Tmax | 2–4 hours |

| Metabolism | Hepatic (via CYP2C19 to Cycloguanil) |

| Excretion | Renal (40–60% as unchanged drug and metabolites) |

• Molecular Formula: C11H16ClN5
• Molecular Weight: 253.73 g/mol (free base); 290.2 g/mol (HCl salt)
• Solubility: Slightly soluble in water; soluble in ethanol.
• Structure: A biguanide derivative consisting of a chlorophenyl group and an isopropyl group attached to a biguanide chain.

Proguanil belongs to the Biguanide class of antimalarials. It is chemically related to the anti-diabetic drug metformin, though its therapeutic targets are entirely different. Other drugs in the antimalarial DHFR-inhibitor category include pyrimidines like pyrimethamine.